Medicaid & GLP-1s:
The State-by-State
Divide

If you are on Medicaid and currently taking a GLP-1 medication for weight loss, or hoping to start one, the coverage landscape has changed significantly in 2026 — and not in your favor. Four states eliminated Medicaid GLP-1 coverage for obesity on January 1, 2026. More are actively considering the same move. Understanding where things stand, and why, matters whether you are trying to plan your treatment or simply trying to understand what is happening.

This is not a story about whether GLP-1 medications work. They do. The clinical evidence is clear. This is a story about money, state budgets, and the gap between what is medically effective and what is politically sustainable to fund.

Why Medicaid Coverage of GLP-1s Is Optional

Under federal law, state Medicaid programs are generally required to cover nearly all FDA-approved drugs for medically accepted indications. However, there is a specific statutory exception for weight-loss drugs. States can choose to exclude them from coverage entirely. This exception has existed for decades — it predates the GLP-1 era — but it has become highly consequential now that GLP-1 medications are both clinically effective and extremely expensive.

Coverage is required when GLP-1s are prescribed for type 2 diabetes, cardiovascular disease risk reduction (Wegovy, since March 2024), or moderate-to-severe obstructive sleep apnea (Zepbound, since December 2024). Coverage is also required for children under Medicaid’s Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefit when deemed medically necessary. But for obesity treatment in adults, states have full discretion.

The cost pressure is real. A monthly supply of semaglutide or tirzepatide carries a list price between $936 and $1,023. Medicaid programs negotiate rebates that reduce that figure, but the net cost is still substantial — and it scales with the number of enrollees who qualify. California estimated that covering GLP-1s under Medi-Cal would cost $85 million in fiscal year 2025–26, rising to $680 million by 2028–29. That kind of trajectory is difficult for any state budget to absorb, particularly when federal Medicaid funding is also under pressure from the 2025 reconciliation law.

What Changed on January 1, 2026

Four states ended Medicaid GLP-1 coverage for obesity treatment effective January 1, 2026: California, New Hampshire, Pennsylvania, and South Carolina. Each cited budget pressure as the primary driver. In California, the cut was part of a broader Medi-Cal cost-containment package. In Pennsylvania, the decision was framed as a temporary measure pending federal action on drug pricing.

The practical impact was immediate. Patients who had been stabilized on semaglutide or tirzepatide for weight management lost their coverage overnight. Without insurance, the out-of-pocket cost of these medications is prohibitive for most Medicaid enrollees, who by definition have low incomes. Manufacturer patient assistance programs exist but have limited capacity and often require navigating significant paperwork.

North Carolina had a similar experience. The state dropped GLP-1 obesity coverage in October 2025, then reversed course and reinstated it in December 2025 — a reversal that reflected both clinical concern and political pressure from providers and patient advocates.

Where Things Stand in Mid-2026

As of July 2026, 11 state Medicaid programs cover GLP-1 medications for obesity treatment under fee-for-service, down from 16 in October 2025. Massachusetts ended coverage on July 1, 2026; Rhode Island will follow on October 1, 2026, which will bring the count to 10. The states currently covering obesity treatment include Delaware, Kansas, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Tennessee, Utah, Virginia, and Wisconsin, along with a small number of others. Coverage terms vary: most require prior authorization, and some have added additional eligibility restrictions.

Michigan, for example, tightened its criteria in early 2026 to limit coverage to patients diagnosed with morbid obesity (BMI ≥ 40, or BMI ≥ 35 with a serious comorbidity) who have already tried other weight-loss treatments without success. The change is expected to save the state an estimated $240 million. It is a meaningful restriction — many patients who would benefit clinically will no longer qualify.

The Federal Picture: BALANCE and What It Might Change

In December 2025, the Trump administration introduced the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) model — a five-year CMS Innovation Center demonstration that aims to expand access to GLP-1 medications in both Medicare and Medicaid by negotiating lower prices directly with manufacturers. State Medicaid programs and manufacturers were asked to submit participation intentions by January 8, 2026, and the model was expected to begin in May 2026.

The BALANCE model is voluntary for state Medicaid programs. It includes standardized coverage criteria and requires participating states to offer lifestyle support programs alongside the medication — a requirement that reflects the clinical evidence that medication works best when paired with behavioral change. Whether the negotiated prices will be low enough to bring back states that have already cut coverage remains to be seen. The model does not mandate coverage; it only makes coverage more financially attractive for states that choose to participate.

The Core Issue

The BALANCE model requires lifestyle support as a condition of participation. That is not a bureaucratic formality — it is the right clinical approach. Medication without a behavioral system is a temporary fix. The states that get this right will pair access with education.

What to Do If You Lose Coverage

If you are in a state that has cut Medicaid GLP-1 coverage for obesity, or if you are concerned about losing coverage, there are several options worth exploring — none of them perfect, but all worth knowing about.

Check whether your diagnosis qualifies for required coverage. If you have type 2 diabetes, your state Medicaid program is required to cover GLP-1 medications. If you have been diagnosed with cardiovascular disease or moderate-to-severe obstructive sleep apnea, coverage may also be required for those indications. Talk to your doctor about whether your clinical picture supports a covered indication.

Ask about manufacturer patient assistance programs. Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) both have patient assistance programs for people who cannot afford their medications. Eligibility requirements and availability vary. Your prescribing doctor or a social worker at your clinic can help you apply.

Check TrumpRx. In November 2025, the Trump administration announced a deal with Eli Lilly and Novo Nordisk to lower GLP-1 prices for people purchasing directly through a new federal website, TrumpRx.gov. The reduced prices are available to uninsured individuals and those whose insurance does not cover the medication. The prices are still not low enough for most Medicaid-income households, but they represent a meaningful reduction from retail list prices.

Consider compounded semaglutide cautiously. During the period when branded GLP-1s were on the FDA shortage list, compounded versions were legally available from certain pharmacies. The FDA removed semaglutide from the shortage list in early 2025, which means compounded semaglutide is no longer legally permitted from most compounding pharmacies. Be cautious of any source offering compounded GLP-1s — verify that the pharmacy is a licensed 503B outsourcing facility and that the compound is FDA-compliant before using it.

The Bigger Picture

The Medicaid GLP-1 coverage story is, at its core, a story about what happens when a highly effective but expensive treatment meets a system that was not designed to fund it at scale. The medications work. The evidence is not in dispute. But “it works” and “the state will pay for it” are two different questions, and right now, more states are answering the second question with “no.”

Almost 40% of adults on Medicaid have obesity. These are not people who can easily absorb a $1,000 monthly medication cost. When coverage disappears, most of them stop taking the medication. And when they stop, the research is clear about what happens next: the weight comes back. Not because they failed, but because the drug was doing the metabolic work that their biology was not doing on its own — and when the drug goes away, so does that effect.

This is why the behavioral component matters so much — not as a moral judgment about willpower, but as a practical strategy for what happens when access is interrupted. The people who do best after losing medication access are the ones who used the window of reduced appetite to build durable habits: tracking their intake, understanding their calorie targets, building a relationship with food that does not depend on pharmaceutical appetite suppression to function.

I lost 170 pounds. I used a GLP-1 as one part of a system. The medication made it easier to stay in a deficit. The system — tracking, learning, building habits — is what made it possible to stay there after the medication ended. That is the part nobody can take away from you, regardless of what your state Medicaid office decides.

← Back to Resources